Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of in-hospital deterioration in normotensive pulmonary embolism remains elusive: external validation of the calgary acute pulmonary embolism score.
Hyder SN, Goraya SR, Grace KA, O'Hare C, Schaeffer WJ, Stover M, Matthews T, Khaja MS, Liles A, Greineder CF, Barnes GD. Hyder SN, et al. Among authors: o hare c. J Thromb Thrombolysis. 2023 Aug;56(2):327-332. doi: 10.1007/s11239-023-02853-3. Epub 2023 Jun 23. J Thromb Thrombolysis. 2023. PMID: 37351823 Free PMC article.
Extracting root fragments.
Edgar H, O'Hare C. Edgar H, et al. Among authors: o hare c. Br Dent J. 2024 Sep;237(5):302. doi: 10.1038/s41415-024-7855-0. Epub 2024 Sep 13. Br Dent J. 2024. PMID: 39271853 No abstract available.
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.
Gros B, Ross H, Nwabueze M, Constantine-Cooke N, Derikx LAAP, Lyons M, O'Hare C, Noble C, Arnott ID, Jones GR, Lees CW, Plevris N. Gros B, et al. Among authors: o hare c. Therap Adv Gastroenterol. 2024 Jul 30;17:17562848241258372. doi: 10.1177/17562848241258372. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39086990 Free PMC article.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17. Lancet. 2024. PMID: 38768626 Clinical Trial.
81 results